Identification SNP rs5219 KCNJ11 gene and blood glucose levels in type 2 diabetes mellitus patients at Moewardi Hospital Surakarta

Authors

  • Nur Aida Program Pascasarjana Farmasi Klinik, Fakultas Farmasi, Universitas Ahmad Dahlan Yogyakarta, Indonesia
  • Rita Maliza Program Studi Biologi, Fakultas Sains dan Teknologi Terapan, Universitas Ahmad Dahlan Yogyakarta, Indonesia
  • Imaniar Noor Faridah Program Studi Farmasi Fakultas Farmasi Universitas Ahmad Dahlan Yogyakarta, Indonesia
  • Melinda Widianingrum Program Studi Biologi, Fakultas Sains dan Teknologi Terapan, Universitas Ahmad Dahlan Yogyakarta, Indonesia
  • Dyah Aryani Perwitasari Program Studi Farmasi Fakultas Farmasi Universitas Ahmad Dahlan Yogyakarta, Indonesia

DOI:

https://doi.org/10.12928/pharmaciana.v11i3.19105

Keywords:

DMT2, Sulfonylurea, KCNJ11, Rs5219, PCR-Sequencing

Abstract

Diabetes Mellitus (DM) is a metabolic disease that developed due to the pancreas does not sufficient to produce insulin or the body cannot effectively use the insulin it produces. Genetic factors have an essential role in the development of Type 2 Diabetes Mellitus (DMT2), which impaired insulin production by pancreatic β cells, insulin resistance, and action. The single nucleotide polymorphisms (SNP) in the KCNJ11 rs5219 affected the pancreatic β cell activity that can inhibit insulin release, thus causing a decrease in therapeutic effectiveness. The purpose of this study is to identify the SNP rs5219 of the KCNJ11 gene and measure patient blood sugar levels as the outcome of therapy. A cross-sectional study was conducted prospectively at Moewardi Hospital, Surakarta, involving 10 patients with DMT2 who received sulfonylureas therapy. DNA was isolated from the whole blood sample of DMT2 patients. PCR amplification was performed to amplify the KCNJ11 gene, and followed by PCR sequencing. The 2-H PP, FPG, and HbA1c parameters were measured as therapeutic outcomes. The results showed that the genotype frequencies (AA-AG-GG) were 10%, 50%, and 40%, while the allele frequency (A-G) in the sample was 35% and 65%. The uncontrolled values for 2H-PP on genotype (AA and AG + GG) were 10% and 20%; uncontrolled FPG on genotypes AA and AG + GG were 10% and 40%; and uncontrolled HbA1c on genotype AA and AG + GG were 10% and 80%. This study conclusion is the presence of the SNP rs5219 KCNJ11 gene with A>G base change in DMT2 patients who received sulfonylurea therapy.

References

Abed, A. A., Ayesh, B. M., & Hamdona, O. M. (2013). Single nucleotide polymorphism E23K of KCNJ11 gene and other risk factors associated with type-2 diabetes mellitus in Gaza. International Journal of Chemical and Life Sciences, 2(04), 1146–1152

Ahn, S. Y., Kim, G. H., & Yoo, H. W. (2015). Successful sulfonylurea treatment in a patient with permanent neonatal diabetes mellitus with a novel KCNJ11 mutation. Korean Journal of Pediatrics, 58(8), 309–312. https://doi.org/10.3345/kjp.2015.58.8.309

American Diabetes Association. (2019). Introduction:Standardsofmedical care in diabetesd2019. In Diabetes Care (Vol. 42, Issue December 2018, pp. S1–S2). https://doi.org/10.2337/dc19-SINT01

Bösenberg, L. H., & Van Zyl, D. G. (2008). The mechanism of action of oral antidiabetic drugs: A review of recent literature. In Journal of Endocrinology, Metabolism and Diabetes of South Africa (Vol. 13, Issue 3, pp. 80–89). https://doi.org/10.1080/22201009.2008.10872177

Ezenwaka, C. E., Kalloo, R., Uhlig, M., Schwenk, R., & Eckel, J. (2005). The E23K variant in the Kir6.2 subunit of the ATP-sensitive K+ channel does not augment impaired glucose tolerance in Caribbean subjects with a family history of type 2 diabetes. Journal of Endocrinology, 185(3), 439–444. https://doi.org/10.1677/joe.1.06117

Felea, M. G., Covrig, M., Mircea, I., & Naghi, L. (2014). Socioeconomic status and risk of type 2 diabetes mellitus among an elderly group population in romania. Procedia Economics and Finance, 10(14), 61–67. https://doi.org/10.1016/s2212-5671(14)00278-0

Gloyn, A. L., Hashim, Y., Ashcroft, S. J. H., Ashfield, R., Wiltshire, S., & Turner, R. C. (2001). Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabetic Medicine, 18(3), 206–212. https://doi.org/10.1046/j.1464-5491.2001.00449.x

Gupta, M. K., & Vadde, R. (2020). A computational structural biology study to understand the impact of mutation on structure–function relationship of inward-rectifier potassium ion channel Kir6.2 in human. Journal of Biomolecular Structure and Dynamics, 0(0), 1–24. https://doi.org/10.1080/07391102.2020.1733666

Haghvirdizadeh, P., Mohamed, Z., Abdullah, N. A., Haghvirdizadeh, P., Haerian, M. S., & Haerian, B. S. (2015). KCNJ11: Genetic polymorphisms and risk of diabetes mellitus. Journal of Diabetes Research, 2015, 1–9. https://doi.org/10.1155/2015/908152

Irawan, D. (2010). Prevalensi dan faktor risiko kejadian diabetes melitus tipe 2 di daerah Urban Indonesia. In Universitas Indonesia. Universitas Indonesia.

Javorsky, M., Klimcakova, L., Schroner, Z., Zidzik, J., Babjakova, E., Fabianova, M., Kozarova, M., Tkacova, R., Salagovic, J., & Tkac, I. (2012). KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. European Journal of Internal Medicine, 23(3), 245–249. https://doi.org/10.1016/j.ejim.2011.10.018

Kementrian Kesehatan RI. (2020). Infodatin tetap produktif, cegah, dan atasi Diabetes Melitus 2020. In Pusat Data dan Informasi Kementrian Kesehatan RI (pp. 1–10). Kementrian Kesehatan.

Khairani. (2019). Hari Diabetes Sedunia Tahun 2018. Pusat Data Dan Informasi Kementrian Kesehatan RI, 1–8

Komariah, K., & Rahayu, S. (2020). Hubungan usia, jenis kelamin dan indeks massa tubuh dengan kadar gula darah puasa pada pasien diabetes melitus tipe 2 di klinik pratama rawat jalan proklamasi, Depok, Jawa Barat. Jurnal Kesehatan Kusuma Husada, January, 41–50. https://doi.org/10.34035/jk.v11i1.412

Li, Q., Chen, M., Zhang, R., Jiang, F., Wang, J., Zhou, J., Bao, Y., Hu, C., & Jia, W. (2014). KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients. Clinical and Experimental Pharmacology and Physiology, 41(10), 748–754. https://doi.org/10.1111/1440-1681.12280

Liu, N. J., Wu, H. H., Li, Y. L., Yang, Z., Tao, X. M., Du, Y. P., Wang, X. C., Lu, B., Zhang, Z. Y., Hu, R. M., & Wen, J. (2015). An analysis of the association between a polymorphism of KCNJ11 and diabetic retinopathy in a Chinese Han population. European Journal of Medical Research, 20(1), 1–7. https://doi.org/10.1186/s40001-014-0075-3

Makhzoom, O., Kabalan, Y., & Al-Quobaili, F. (2019). Association of KCNJ11 rs5219 gene polymorphism with type 2 diabetes mellitus in a population of Syria: A case-control study. BMC Medical Genetics, 20(1), 1–6. https://doi.org/10.1186/s12881-019-0846-3

Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., Shaw, J. E., Bright, D., & Williams, R. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice, 157(January), 107843. https://doi.org/10.1016/j.diabres.2019.107843

Sesti, G., Laratta, E., Cardellini, M., Andreozzi, F., Del Guerra, S., Irace, C., Gnasso, A., Grupillo, M., Lauro, R., Hribal, M. L., Perticone, F., & Marchetti, P. (2006). The E23K variant of KCNJ11 encoding the pancreatic β-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 91(6), 2334–2339. https://doi.org/10.1210/jc.2005-2323

Sisi, A. E., Metwally, S. S., & Dawood, N. A. (2011). Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in Egyptian patients with type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2(4), 155–164. https://doi.org/10.1177/2042018811415985

Song, J., Yang, Y., Mauvais-Jarvis, F., Wang, Y. P., & Niu, T. (2017). KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: A bioinformatics assessment. BMC Medical Genetics, 18(1), 1–17. https://doi.org/10.1186/s12881-017-0422-7

Varanka-Ruuska, T., Rautio, N., Lehtiniemi, H., Miettunen, J., Keinänen-Kiukaanniemi, S., Sebert, S., & Ala-Mursula, L. (2018). The association of unemployment with glucose metabolism: a systematic review and meta-analysis. International Journal of Public Health, 63(4), 435–446. https://doi.org/10.1007/s00038-017-1040-z

Wu, Y., Ding, Y., Tanaka, Y., & Zhang, W. (2014). Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. In International journal of medical sciences, 11(11), 1185–1200). https://doi.org/10.7150/ijms.10001

Downloads

Published

2021-10-23

Issue

Vol. 11 No. 3 (2021): Pharmaciana

Section

Clinical and Community Pharmacy

License

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.